Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Wyeth Complains China IND Process Is Too Slow

publication date: Apr 8, 2008

Wyeth (NYSE: WYE) told Interfax that it would not create an R&D center in China because the SFDA takes too long to approve initial clinical trials (see article). The IND process in the US and Europe involves only a 30-day waiting period, but the same process in China can be nine months or more. On the other hand, even though it will not establish an R&D center in China, Wyeth said it would make several moves to increase its use of China’s R&D expertise. More details...

Stock Symbol: (NYSE: WYE)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital